Physician profile
Perry J Roy
NPI 1477526184
$134,563.70
in general payments reported to CMS, 2019-2025
17 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $630 · 2021: $26K · 2022: $39K · 2023: $24K · 2024: $21K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Honoraria: $16K · Consulting Fee: $6,420 · Food and Beverage: $6,203 · Travel and Lodging: $5,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,440.00 |
| Honoraria | $16,100.00 |
| Consulting Fee | $6,420.00 |
| Food and Beverage | $6,203.40 |
| Travel and Lodging | $5,747.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $30,753.62 | 2021-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $28,841.08 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $23,596.00 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $23,007.45 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Collegium Pharmaceutical, INC. | $16,759.19 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $5,464.74 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Aytu Biopharma, INC. | $4,529.63 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $544.77 | 2019-2022 | |
| Noven Therapeutics, LLC | $477.19 | 2022-2025 | Xelstrym, Secuado |
| Adlon Therapeutics L.P. | $248.57 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $100.83 | 2019-2024 | Relexxii |
| Arbor Pharmaceuticals, INC. | $80.57 | 2019 | |
| Shire North American Group INC | $75.63 | 2019 | |
| Avion Pharmaceuticals | $36.07 | 2023 | Methylphenidate Hydrochloride |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.19 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $15.89 | 2024 | Xelstrym |
| Rhodes Pharmaceuticals L.P. | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.